HF 10

Drug Profile

HF 10

Alternative Names: HF-10; Msc 2; TBI-1401

Latest Information Update: 06 Dec 2016

Price : $50

At a glance

  • Originator Ms Science; Nagoya University
  • Developer Takara Bio
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Malignant melanoma
  • Phase I Head and neck cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 17 May 2017 Takara Bio plans a phase II trial for Malignant melanoma (Combination therapy, Metastatic disease, Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in Japan (NCT03153085)
  • 07 Oct 2016 Adverse events and efficacy data from a phase II trial in Malignant melanoma presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
  • 12 Aug 2015 Takara terminates phase I trial in Solid tumours in Japan (UMIN000007263)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top